Al-Razi Medical Company (9572) Fair Value & Analysis
Healthcare · SA · Market cap 42.4M SAR
Fair value as of: Aug 1, 2026
From 24 valuation models · updated today
Share price −12.5% over the past month.
What matters now
- The price sits above even our optimistic bull case (13.48 SAR). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (12 months)
12‑month range 25.10 SAR – 41.50 SAR · fair‑value band 8.09 SAR – 13.48 SAR · the 27.92 SAR price screens above the 10.78 SAR fair value. As of Aug 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Al-Razi Medical Company (9572) currently trades at 27.92 SAR, while our model-based Fair Value estimate is 10.78 SAR, implying the stock looks roughly 61.4% overvalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Al-Razi Medical Company generated revenue of 74.4M SAR at a net margin of 1.1%. Revenue grew 34.0% year over year. It earns a return on equity of 3.6%. Net debt stands at 2.5M SAR. Fundamentals as of Aug 1, 2026
Our scenario range runs from 8.09 SAR (bear case) to 13.48 SAR (bull case); at 27.92 SAR, the current price sits above that range. The share trades about 33% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 15% fair-value upside, at -61%, 9572 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Al-Razi Medical Company engages in the retail sale of medical devices, equipment, and supplies in the Kingdom of Saudi Arabia. The company is involved in the operation of medical device, cosmetic, and pharmaceutical warehouses; specialized and general medical complexes; and one-day surgery centers.
Full company description
Al-Razi Medical Company engages in the retail sale of medical devices, equipment, and supplies in the Kingdom of Saudi Arabia. The company is involved in the operation of medical device, cosmetic, and pharmaceutical warehouses; specialized and general medical complexes; and one-day surgery centers. It also engages in the land transport of goods; operation of storage facilities; and provision of shipping and distribution services. The company was founded in 1986 and is headquartered in Riyadh, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Al-Razi Medical Company reported revenue of 74.4M SAR in FY2025 versus 45.2M SAR in FY2021, a compound +13.3%/yr. Reported net income was 819K SAR in FY2025, compounding −21.5%/yr from FY2021.
Is 9572 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$17.76 | R$14.97 | -16% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $27.97 | $34.29 | +23% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $29.34 | -1% |
| DaShenLin Pharmaceutical Group 603233 | ¥16.68 | ¥19.21 | +15% |
| Redcare Pharmacy NV RDC | €66.40 | €124.16 | +87% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.74 | ¥10.57 | -10% |
Compare Al-Razi Medical Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Al-Razi Medical Company (9572) overvalued or undervalued?
What is the fair value of 9572?
What is the quality score of 9572?
What is the revenue of Al-Razi Medical Company (9572)?
What is the net profit margin of 9572?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Al-Razi Medical Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.